• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Susan Escudier: OCM Improvements That Practices Should Continue

Video

Even though the Oncology Care Model (OCM) ended on June 30, 2022, there are some improvements that practices should continue implementing, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.

Even though the Oncology Care Model (OCM) ended on June 30, 2022, there are some improvements that practices should continue implementing, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.

Note: This interview took place prior to the June 30, 2022, end of the OCM.

Transcript

What do you hope or expect practices will continue to do even after the OCM ends?

I think the things, to me, that were important: I like our standardized treatment plans. I find them to be a nice teaching tool for the patient to explain their diagnosis, their prognosis. I hand it to them. I hand them a drug handout. They go home, they share it with their family. It's a nice way for them to be able to go home and study the information and think about it. Also, sometimes they forget what we tell them, so it’s helpful for that aspect.

I think the patient outreach—like calling patients after treatments—I think that should stick around. I think one of our big wins was being able to cut the turnaround time on getting patient calls answered. I think that's a big win we need to keep.

I think there are a lot of improvements that were made—our depression screenings, our distress screenings increased—and those are things we really need to keep doing going forward.

Related Videos
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.